Imaging and Tissue Biomarkers of Choline Metabolism in Diffuse Adult Glioma: 18F-Fluoromethylcholine PET/CT, Magnetic Resonance Spectroscopy, and Choline Kinase α.
MRI
PET
brain
choline
glioma
Journal
Cancers
ISSN: 2072-6694
Titre abrégé: Cancers (Basel)
Pays: Switzerland
ID NLM: 101526829
Informations de publication
Date de publication:
07 Dec 2019
07 Dec 2019
Historique:
received:
29
10
2019
revised:
28
11
2019
accepted:
03
12
2019
entrez:
11
12
2019
pubmed:
11
12
2019
medline:
11
12
2019
Statut:
epublish
Résumé
The cellular and molecular basis of choline uptake on PET imaging and MRS-visible choline-containing compounds is not well understood. Choline kinase alpha (ChoKα) is an enzyme that phosphorylates choline, an essential step in membrane synthesis. We investigate choline metabolism through 18F-fluoromethylcholine (18F-FMC) PET, MRS, and tissue ChoKα in human glioma. Fourteen patients with a suspected diffuse glioma underwent multimodal 3T MRI and dynamic 18F-FMC PET/CT prior to surgery. Co-registered PET and MRI data were used to target biopsies to regions of high and low choline signal, and immunohistochemistry for ChoKα expression was performed. The 18F-FMC/PET differentiated WHO (World Health Organization) grade IV from grade II and III tumours, whereas MRS differentiated grade III/IV from grade II tumours. Tumoural 18F-FMC/PET uptake was higher than in normal-appearing white matter across all grades and markedly elevated within regions of contrast enhancement. The 18F-FMC/PET correlated weakly with MRS Cho ratios. ChoKα expression on IHC was negative or weak in all but one glioblastoma sample, and did not correlate with tumour grade or imaging choline markers. MRS and 18F-FMC/PET provide complimentary information on glioma choline metabolism. Tracer uptake is, however, potentially confounded by blood-brain barrier permeability. ChoKα overexpression does not appear to be a common feature in diffuse glioma.
Identifiants
pubmed: 31817833
pii: cancers11121969
doi: 10.3390/cancers11121969
pmc: PMC6966628
pii:
doi:
Types de publication
Journal Article
Langues
eng
Subventions
Organisme : National Institute for Health Research Imperial Biomedical Research Centre
ID : N/A
Organisme : Brain Tumour Charity
ID : 33 / 159
Organisme : Brain Tumour Research Campaign
ID : N/A
Références
Radiology. 2007 Aug;244(2):557-65
pubmed: 17581887
Lancet Oncol. 2017 Dec;18(12):1579-1589
pubmed: 29111259
AJNR Am J Neuroradiol. 2000 Apr;21(4):659-65
pubmed: 10782774
NMR Biomed. 1999 Nov;12(7):413-39
pubmed: 10654290
Semin Nucl Med. 2017 Jan;47(1):5-17
pubmed: 27987557
J Neurooncol. 2008 Apr;87(2):181-7
pubmed: 18163185
J Neurosurg. 2017 Oct;127(4):812-818
pubmed: 27834593
Biochim Biophys Acta. 1997 Sep 4;1348(1-2):70-8
pubmed: 9370318
J Neurosurg. 1997 Oct;87(4):516-24
pubmed: 9322842
J Clin Neurosci. 2005 May;12(4):416-20
pubmed: 15925772
AJNR Am J Neuroradiol. 1995 Sep;16(8):1593-603
pubmed: 7502961
Nat Rev Cancer. 2011 Nov 17;11(12):835-48
pubmed: 22089420
Acta Neuropathol. 2016 Jun;131(6):803-20
pubmed: 27157931
Cancer Res. 2009 Oct 1;69(19):7721-8
pubmed: 19773436
Magn Reson Med. 2011 Jan;65(1):1-12
pubmed: 20878762
Clin Nucl Med. 2012 Aug;37(8):e196-203
pubmed: 22785527
NMR Biomed. 2009 Jul;22(6):629-37
pubmed: 19322812
Cancer Res. 1999 Jan 1;59(1):80-4
pubmed: 9892190
Neuroradiology. 2000 May;42(5):333-8
pubmed: 10872152
J Neurosurg. 2003 Sep;99(3):474-9
pubmed: 12959432
Biochem Biophys Res Commun. 2002 Aug 23;296(3):580-3
pubmed: 12176020
J Nucl Med. 2001 Dec;42(12):1805-14
pubmed: 11752077